← Leaderboards
Rama Rao Amara
Emory University
$90,840,294
Attributed
$131,055,183
Total exposure
53
Grants
44
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $14.6M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$179,245,771 · 56
By mechanism
UM1$68,621,468 · 2
U19$52,551,034 · 8
R01$26,146,957 · 8
P01$17,531,259 · 5
R37$9,172,578 · 1
P51$1,871,155 · 27
Top collaborators
- Eric Hunter16 shared
- Steven Edward Bosinger6 shared
- Lishan Su6 shared
- Vijayakumar Velu5 shared
- Benjamin A Lopman4 shared
- Nadine Georges Rouphael4 shared
- David Masopust1 shared
Most similar at Emory University
Same institution · by research overlap
- Harriet L Robinson$13,479,393
- Guido Silvestri$61,186,493
- Swaminathan Smita Iyer$7,083,425
- John D Altman$1,711,771
- Mark B. Feinberg$16,950,022
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionMacacaT-LymphocyteVaccinesVaccinationMacaca MulattaVirusResponseImmunityViralAdjuvantAntigensAntibodiesCd8b1 GeneT Cell ResponseCellsHiv VaccineB-LymphocytesSafetyImmune ResponseImmuneCd4 Positive T LymphocytesProgramsProteins
Grant awards (145)
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection$5,678,616
UM1 · FY2025 · AI
Targeting PD-1 Pathway for Functional Cure of AIDS$880,613
R01 · FY2025 · AI · contact PI
Training a new generation of vaccinologists$464,434
T32 · FY2025 · AI
Emory Vaccinology Training Program (VTP-T32)$109,602
T32 · FY2025 · AI
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection$5,678,510
UM1 · FY2024 · AI
Targeting PD-1 Pathway for Functional Cure of AIDS$928,498
R01 · FY2024 · AI · contact PI
Combined cytokine therapy for sustained HIV remission$892,227
R01 · FY2024 · AI
Correlates of protective immunity to HCV and rational vaccine design: Project 3$838,357
U19 · FY2024 · AI · contact PI
Training a new generation of vaccinologists$435,985
T32 · FY2024 · AI
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection$429,899
UM1 · FY2024 · AI
Training a new generation of vaccinologists$96,453
T32 · FY2024 · AI
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection$8,713,338
UM1 · FY2023 · AI
Combined cytokine therapy for sustained HIV remission$1,021,416
R01 · FY2023 · AI
Correlates of protective immunity to HCV and rational vaccine design: Project 3$957,184
U19 · FY2023 · AI · contact PI
Targeting PD-1 Pathway for Functional Cure of AIDS$807,098
R37 · FY2023 · AI · contact PI
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection$5,814,430
UM1 · FY2022 · AI
Combined cytokine therapy for sustained HIV remission$891,222
R01 · FY2022 · AI
Targeting PD-1 Pathway for Functional Cure of AIDS$826,489
R37 · FY2022 · AI · contact PI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs$814,022
R01 · FY2022 · AI
MVA Prime/Novel Trimeric Cyclically Permuted Envelope Protein Boost Vaccines for HIV$785,398
R01 · FY2022 · AI · contact PI
Correlates of protective immunity to HCV and rational vaccine design: Project 3$408,060
U19 · FY2022 · AI · contact PI
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection - Administrative Supplement$6,714,942
UM1 · FY2021 · AI
Combined cytokine therapy for sustained HIV remission$890,185
R01 · FY2021 · AI
Targeting PD-1 Pathway for Functional Cure of AIDS$849,204
R37 · FY2021 · AI · contact PI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs$833,168
R01 · FY2021 · AI
MVA Prime/Novel Trimeric Cyclically Permuted Envelope Protein Boost Vaccines for HIV$766,724
R01 · FY2021 · AI · contact PI
Correlates of protective immunity to HCV and rational vaccine design: Project 3$692,666
U19 · FY2021 · AI · contact PI
MVA based SARS-CoV-2 vaccines$187,664
R01 · FY2021 · AI · contact PI
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection$6,632,717
UM1 · FY2020 · AI
Targeting PD-1 Pathway for Functional Cure of AIDS$1,467,069
R37 · FY2020 · AI · contact PI
Combined cytokine therapy for sustained HIV remission$891,856
R01 · FY2020 · AI
Optimizing Adjuvants and Needle Free Delivery Methods for Oral HIV Vaccination$788,873
R01 · FY2020 · DE · contact PI
MVA Prime/Novel Trimeric Cyclically Permuted Envelope Protein Boost Vaccines for HIV$767,322
R01 · FY2020 · AI · contact PI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs$539,240
R01 · FY2020 · AI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs$311,116
R01 · FY2020 · AI
MVA based SARS-CoV-2 vaccines$292,855
R01 · FY2020 · AI · contact PI
MVA based SARS-CoV-2 vaccines$102,106
R01 · FY2020 · AI · contact PI
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection$7,450,948
UM1 · FY2019 · AI
Targeting PD-1 Pathway for Functional Cure of AIDS$911,104
R37 · FY2019 · AI · contact PI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs$842,342
R01 · FY2019 · AI
Optimizing Adjuvants and Needle Free Delivery Methods for Oral HIV Vaccination$815,685
R01 · FY2019 · DE · contact PI
MVA Prime/Novel Trimeric Cyclically Permuted Envelope Protein Boost Vaccines for HIV$766,533
R01 · FY2019 · AI · contact PI
Optimizing Adjuvants and Needle Free Delivery Methods for Oral HIV Vaccination$628,384
R01 · FY2019 · DE · contact PI
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection$7,210,333
UM1 · FY2018 · AI
CD40L adjuvanted clade C DNA and MVA HIV vaccines$1,888,340
U19 · FY2018 · AI · contact PI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs$862,217
R01 · FY2018 · AI
Targeting PD-1 Pathway for Functional Cure of AIDS$832,850
R37 · FY2018 · AI · contact PI
Optimizing Adjuvants and Needle Free Delivery Methods for Oral HIV Vaccination$754,852
R01 · FY2018 · DE · contact PI
Preclinical Studies and T cell Responses$640,701
U19 · FY2018 · AI · contact PI
CD40L Adjuvanted Clade C DNA and MVA HIV Vaccines -Administrative Core$196,491
U19 · FY2018 · AI · contact PI
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection$6,923,840
UM1 · FY2017 · AI
CD40L adjuvanted clade C DNA and MVA HIV vaccines$1,917,505
U19 · FY2017 · AI · contact PI
Targeting PD-1 Pathway for Functional Cure of AIDS$844,556
R37 · FY2017 · AI · contact PI
Optimizing Adjuvants and Needle Free Delivery Methods for Oral HIV Vaccination$833,778
R01 · FY2017 · DE · contact PI
Preclinical Studies and T cell Responses$623,525
U19 · FY2017 · AI · contact PI
CD40L Adjuvanted Clade C DNA and MVA HIV Vaccines -Administrative Core$179,782
U19 · FY2017 · AI · contact PI
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection$7,373,895
UM1 · FY2016 · AI
CD40L adjuvanted clade C DNA and MVA HIV vaccines$2,431,541
U19 · FY2016 · AI · contact PI
Optimizing Adjuvants and Needle Free Delivery Methods for Oral HIV Vaccination$858,438
R01 · FY2016 · DE · contact PI
Targeting PD-1 Pathway for Functional Cure of AIDS$858,361
R37 · FY2016 · AI · contact PI
Preclinical Studies and T cell Responses$810,927
U19 · FY2016 · AI · contact PI
CD40L Adjuvanted Clade C DNA and MVA HIV Vaccines -Administrative Core$212,442
U19 · FY2016 · AI · contact PI
B-cell Biology of Mucosal Immune Protection from SIV Challenge$4,854,281
U19 · FY2015 · AI
CD40L adjuvanted clade C DNA and MVA HIV vaccines$1,973,313
U19 · FY2015 · AI · contact PI
Targeting PD-1 Pathway for Functional Cure of AIDS$869,526
R37 · FY2015 · AI · contact PI
Preclinical Studies and T cell Responses$671,635
U19 · FY2015 · AI · contact PI
Immune Correlates for GM-CSF Mediated Enhancement of Vaccine Efficacy$491,764
U19 · FY2015 · AI · contact PI
CD40L Adjuvanted Clade C DNA and MVA HIV Vaccines -Administrative Core$182,567
U19 · FY2015 · AI · contact PI
B-cell Biology of Mucosal Immune Protection from SIV Challenge$5,335,074
U19 · FY2014 · AI
CD40L adjuvanted clade C DNA and MVA HIV vaccines$2,000,000
U19 · FY2014 · AI · contact PI
Targeting PD-1 Pathway for Functional Cure of AIDS$906,321
R37 · FY2014 · AI · contact PI
Preclinical Studies and T cell Responses$636,824
U19 · FY2014 · AI · contact PI
Immune Correlates for GM-CSF Mediated Enhancement of Vaccine Efficacy$506,924
U19 · FY2014 · AI · contact PI
CD40L Adjuvanted Clade C DNA and MVA HIV Vaccines -Administrative Core$227,175
U19 · FY2014 · AI · contact PI
B-cell Biology of Mucosal Immune Protection from SIV Challenge$5,076,283
U19 · FY2013 · AI
Targeting mTOR and CD40 Pathways for Adjuvanting HIV Vaccines$3,079,095
P01 · FY2013 · AI · contact PI
CD40L-Adjuvanted Vaccines for HIV/AIDS$2,152,839
P01 · FY2013 · AI · contact PI
Immune Correlates for GM-CSF Mediated Enhancement of Vaccine Efficacy$670,639
U19 · FY2013 · AI · contact PI
Administrative Core$323,012
P01 · FY2013 · AI · contact PI
31st Annual Symposium on Nonhuman Primate Models for AIDS$72,000
R13 · FY2013 · OD · contact PI
B-cell Biology of Mucosal Immune Protection from SIV Challenge$5,826,449
U19 · FY2012 · AI
Targeting mTOR and CD40 Pathways for Adjuvanting HIV Vaccines$1,739,953
P01 · FY2012 · AI · contact PI
Immune Correlates for GM-CSF Mediated Enhancement of Vaccine Efficacy$886,008
U19 · FY2012 · AI · contact PI
CD40L-Adjuvanted Vaccines for HIV/AIDS$578,471
P01 · FY2012 · AI · contact PI
Administrative Core$151,471
P01 · FY2012 · AI · contact PI
B-cell Biology of Mucosal Immune Protection from SIV Challenge$5,457,454
U19 · FY2011 · AI
Targeting mTOR and CD40 Pathways for Adjuvanting HIV Vaccines$4,170,549
P01 · FY2011 · AI · contact PI
Preclinical Studies and Mucosal Responses$1,386,249
U19 · FY2011 · AI · contact PI
CD40L-Adjuvanted Vaccines for HIV/AIDS$1,237,954
P01 · FY2011 · AI · contact PI
PD-1 blockade as a therapy for SIV/AIDS$853,656
R56 · FY2011 · AI · contact PI
Administrative Core$581,503
P01 · FY2011 · AI · contact PI
Immune Correlates for GM-CSF Mediated Enhancement of Vaccine Efficacy$517,753
U19 · FY2011 · AI · contact PI
PD-1 BLOCKADE AS A THERAPY FOR SIV/AIDS$74,294
P51 · FY2011 · RR · contact PI
TARGETING MTOR AND CD40 PATHWAYS FOR ADJUVANTING HIV VACCINE$74,294
P51 · FY2011 · RR · contact PI
PD-1 BLOCKADE COMBINED WITH VACCINATION AS A THERAPY FOR SIV/AIDS$74,294
P51 · FY2011 · RR · contact PI
PROJECT 2 PRECLINICAL STUDIES AND MUCOSAL RESPONSES$74,294
P51 · FY2011 · RR · contact PI
PD-1 LIGAND BLOCKADE AS A THERAPY FOR SIV$59,500
P51 · FY2011 · RR · contact PI
THERAPEUTIC DNA/MVA VACCINES FOR HIV/AIDS$59,500
P51 · FY2011 · RR · contact PI
Targeting mTOR and CD40 Pathways for Adjuvanting HIV Vaccines$2,440,751
P01 · FY2010 · AI · contact PI
Preclinical Studies and Mucosal Responses$1,283,173
U19 · FY2010 · AI · contact PI
PD-1 blockade as a therapy for SIV/AIDS$840,757
R01 · FY2010 · AI · contact PI
CD40L-Adjuvanted Vaccines for HIV/AIDS$676,482
P01 · FY2010 · AI · contact PI
PD-1 blockade combined with vaccination as a therapy for SIV/AIDS$499,206
RC2 · FY2010 · CA · contact PI
Administrative Core$399,179
P01 · FY2010 · AI · contact PI
PD-1 BLOCKADE COMBINED WITH VACCINATION AS A THERAPY FOR SIV/AIDS$54,827
P51 · FY2010 · RR · contact PI
PD-1 BLOCKADE AS A THERAPY FOR SIV/AIDS$54,827
P51 · FY2010 · RR · contact PI
PROJECT 2 PRECLINICAL STUDIES AND MUCOSAL RESPONSES$54,827
P51 · FY2010 · RR · contact PI
DEVELOPMENT OF NEW GENERATION MUCOSAL SUBUNIT VACCINE AGAINST TUBERCULOSIS$54,827
P51 · FY2010 · RR · contact PI
PD-1 LIGAND BLOCKADE AS A THERAPY FOR SIV$43,862
P51 · FY2010 · RR · contact PI
THERAPEUTIC DNA/MVA VACCINES FOR HIV/AIDS$43,862
P51 · FY2010 · RR · contact PI
Therapeutic DNA/MVA Vaccines for HIV$1,270,020
R01 · FY2009 · AI · contact PI
Preclinical Studies and Mucosal Responses$1,244,087
U19 · FY2009 · AI · contact PI
PD-1 blockade as a therapy for SIV/AIDS$717,280
R01 · FY2009 · AI · contact PI
PD-1 blockade combined with vaccination as a therapy for SIV/AIDS$499,984
RC2 · FY2009 · CA · contact PI
PROJECT 2 PRECLINICAL STUDIES AND MUCOSAL RESPONSES$56,690
P51 · FY2009 · RR · contact PI
THERAPEUTIC DNA/MVA VACCINES FOR HIV/AIDS$56,690
P51 · FY2009 · RR · contact PI
PD-1 LIGAND BLOCKADE AS A THERAPY FOR SIV$56,690
P51 · FY2009 · RR · contact PI
PD-1 BLOCKADE AS A THERAPY FOR SIV/AIDS$56,690
P51 · FY2009 · RR · contact PI
DEVELOPMENT OF NEW GENERATION MUCOSAL SUBUNIT VACINE AGAINST TUBERCULOSIS$54,800
P51 · FY2009 · RR · contact PI
Therapeutic DNA/MVA Vaccines for HIV$780,815
R01 · FY2008 · AI · contact PI
Preclinical Studies and Mucosal Responses$771,455
U19 · FY2008 · AI · contact PI
PD-1 blockade as a therapy for SIV/AIDS$716,507
R01 · FY2008 · AI · contact PI
NOVEL THERAPEUTIC VACCINE FOR HIV/AIDS$95,198
P51 · FY2008 · RR · contact PI
POXVIRUS IMMUNITY AND DNA/MVA HIV VACCINES$67,958
P51 · FY2008 · RR · contact PI
THERAPEUTIC DNA/MVA VACCINES FOR HIV/AIDS$67,958
P51 · FY2008 · RR · contact PI
IMMUNOLOGICAL STRATEGIES FOR CURING CHRONIC HEPATITIS VIRUS$35,600
P51 · FY2008 · RR · contact PI
Therapeutic DNA/MVA Vaccines for HIV$810,264
R01 · FY2007 · AI · contact PI
Preclinical Studies and Mucosal Responses$754,406
U19 · FY2007 · AI · contact PI
Poxvirus Immunity and DNA/MVA HIV Vaccines$313,390
R01 · FY2007 · AI · contact PI
NOVEL THERAPEUTIC VACCINE FOR HIV/AIDS$91,637
P51 · FY2007 · RR · contact PI
POXVIRUS IMMUNITY AND DNA/MVA HIV VACCINES$91,635
P51 · FY2007 · RR · contact PI
Poxvirus Immunity and DNA/MVA HIV Vaccines$430,051
R01 · FY2006 · AI · contact PI
POXVIRUS IMMUNITY AND DNA/MVA HIV VACCINES$59,665
P51 · FY2006 · RR · contact PI
Poxvirus Immunity and DNA/MVA HIV Vaccines$448,777
R01 · FY2005 · AI
THERAPEUTIC VACCINES FOR HIV$52,438
P51 · FY2005 · RR
POXVIRUS IMMUNITY AND DNA/MVA HIV VACCINES$52,438
P51 · FY2005 · RR
MVA/HIV-48 DUAL VACCINE FOR HIV &SMALLPOX$51,389
P51 · FY2005 · RR
Poxvirus Immunity and DNA/MVA HIV Vaccines$629,365
R01 · FY2004 · AI
POXVIRUS IMMUNITY AND DNA/MVA HIV VACCINES$51,707
P51 · FY2004 · RR
THERAPEUTIC VACCINES FOR HIV$51,707
P51 · FY2004 · RR
MVA/HIV-48 DUAL VACCINE FOR HIV &SMALLPOX$50,633
P51 · FY2004 · RR
Poxvirus Immunity and DNA/MVA HIV Vaccines$242,997
R01 · FY2003 · AI
MVA/HIV-48: Potential Dual Vaccine for HIV and Smallpox$160,000
R21 · FY2003 · AI
MVA/HIV-48 DUAL VACCINE FOR HIV &SMALLPOX$46,424
P51 · FY2003 · RR
MVA/HIV-48: Potential Dual Vaccine for HIV and Smallpox$160,000
R21 · FY2002 · AI